Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.

Autor: LaPelusa, Michael1 (AUTHOR) aliya.qayyum@moffitt.org, Chamseddine, Shadi2 (AUTHOR), Tran Cao, Hop Sanderson3 (AUTHOR), Xiao, Lianchun4 (AUTHOR), Hasanov, Elshad5 (AUTHOR), Bhosale, Priya6 (AUTHOR), Amin, Hesham M.7 (AUTHOR), Mohamed, Yehia I.2 (AUTHOR), Gok Yavuz, Betul8 (AUTHOR), Sakr, Yara3 (AUTHOR), Xu, Li2 (AUTHOR), Hu, Ian2 (AUTHOR), Lee, Sunyoung S.2 (AUTHOR), Sakamuri, Divya2 (AUTHOR), Jindal, Sonali9 (AUTHOR), Nguyen, Van10 (AUTHOR), Curran, Michael A.11 (AUTHOR), Sun, Ryan4 (AUTHOR), Rashid, Asif12 (AUTHOR), Duda, Dan Gabriel13 (AUTHOR)
Zdroj: Oncology. Oct2024, p1-8. 8p. 4 Illustrations, 3 Charts.
Databáze: Academic Search Ultimate